Development and validation of an UHPLC-MS/MS method for β2-agonists quantification in human urine and application to clinical samples

A fast analytical method for the simultaneous detection of 24 beta(2)-agonists in human urine was developed and validated. The method covers the therapeutic drugs most commonly administered, but also potentially abused beta(2)-agonists. The procedure is based on enzymatic deconjugation with beta-glucuronidase followed by SPE clean up using mixed-phase cartridges with both ion-exchange and lipophilic properties. Instrumental analysis conducted by UHPLC-MS/MS allowed high peak resolution and rapid chromatographic separation, with reduced time and costs. The method was fully validated according ISO 17025:2005 principles. The following parameters were determined for each analyte: specificity, selectivity, linearity, limit of detection, limit of quantification, precision, accuracy, matrix effect, recovery and carry-over. The method was tested on real samples obtained from patients subjected to clinical treatment under chronic or acute therapy with either formoterol, indacaterol, salbutamol, or salmeterol. The drugs were administered using pressurized metered dose inhalers. All beta(2)-agonists administered to the patients were detected in the real samples. The method proved adequate to accurately measure the concentration of these analytes in the real samples. The observed analytical data are discussed with reference to the administered dose and the duration of the therapy. (C) 2017 Elsevier B.V. All rights reserved.